Compare TYGO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TYGO | MOLN |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.0M | 154.2M |
| IPO Year | 2021 | 2021 |
| Metric | TYGO | MOLN |
|---|---|---|
| Price | $1.17 | $4.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $8.38 |
| AVG Volume (30 Days) | ★ 1.7M | 1.0K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.12 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $103,536,000.00 | N/A |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $21.68 | $374.07 |
| P/E Ratio | $123.00 | ★ N/A |
| Revenue Growth | ★ 91.68 | N/A |
| 52 Week Low | $0.93 | $3.46 |
| 52 Week High | $5.33 | $5.36 |
| Indicator | TYGO | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 28.84 | 54.69 |
| Support Level | N/A | $3.91 |
| Resistance Level | $1.73 | $4.13 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 20.26 | 71.41 |
Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.